Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 4/20 | 0.47 |
| ▸ | CES1 | P23141 | 4/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358014 | 0.86 | ATM (0.64) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL2329814 | 0.82 | ATM (0.55) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL10716596 | 0.82 | ATM (0.55) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL2861674 | 0.82 | ATM (0.60) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL11599419 | 0.81 | SMN1; SMN2 (0.48) | ATMGAANPC1RAB9AALDH1A1 | |
| SCHEMBL8478316 | 0.80 | ATM (0.58) | ATMGAAHSP90AA1NPC1RAB9A | |
| Water SCHEMBL7994044 | 0.80 | ATM (0.53) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL29254343 | 0.78 | ATM (0.56) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL276423 | 0.78 | ATM (0.56) | ATMGAAHSP90AA1NPC1RAB9A | |
| SCHEMBL600051 | 0.77 | TDP1 (0.52) | ATMNPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850083-A | Preparation method of carboxylic acid compounds | 南京正荣医药化学有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2016-10-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| EP-0649425-B1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | UPJOHN CO (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5597816-A | Pyrazoloazepino substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1997-01-28 | — | — | US | disclosed |
| US-5565468-A | 4,5,6,7-TETRAHYDROPYRAZOLO(1,5-A)PYRID-3-YL, PYRAZOLO(1,5-A)PYRID-3-YL, IMIDAZO(1,5-A)PYRIDIN-1-YL OR IMIDAZO(1,2-A)-PYRID-3-YL OXIME DERIVATIVES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5523318-A | Pyrrolidino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0649425-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| CN-1081678-A | Multi-agent is crossed as atherosclerosis and antihypercholesterolemic in the oximes that pyridyl, pyrrolidyl and azepines base replace and they | UPJOHN CO (US) | 1994-02-09 | — | — | CN | disclosed |
| WO-1993025553-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | THE UPJOHN COMPANY (US) | 1993-12-23 | — | — | WO | disclosed |
| CN-1040197-A | SUBSTITUTED PHENYLTRIAZOLOPYRIMIDINE HERBICIDES | DU PONT (US) | 1990-03-07 | — | — | CN | disclosed |
| US-4275200-A | CONDENSATION OF CARBAMIC ESTERS WITH X-HALOGEN CARBONYL COMPOUNDS | AGFA-GEVAERT, A.G. (DE) | 1981-06-23 | — | — | US | disclosed |
| US-4059447-A | Photographic material containing oxazolinone-2 couplers | AGFA-GEVAERT AKTIENGESELLSCHAFT (DT) | 1977-11-22 | — | — | US | disclosed |
| US-4046759-A | INTERMEDIATES FOR CEPHALOSPORINS | ISHIMARU TOSHIYASU | 1977-09-06 | — | — | US | disclosed |
| US-3946057-A | ALKYLENE OXIDE, METAL HALIDE, POLAR SOLVENT | UNION CARBIDE CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303128-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | ATM 431/4885GAA 1799/4885HSP90AA1 1362/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | ATM 431/4885GAA 1799/4885HSP90AA1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.